Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA Defends Adaptive Pathways Against Fresh Attack Following Pilot Report

Executive Summary

The European Medicines Agency has dismissed a call to stop accepting applications for its adaptive pathways program until it has better evidence on how to use real-world data.

You may also be interested in...



Bayer’s Adaptive Pathways Experience: 'Disappointing', But Valuable Lessons Learned

Bayer outlined its initial experience with the European Medicines Agency’s adaptive pathways pilot at the recent DIA EuroMeeting in Glasgow, saying that the process had been “disappointing” but that it had learned some valuable lessons.

EU HTA Bodies, Payers Look At Ways To Fill Evidence Gaps In Early Access Schemes

While the German pricing and reimbursement authority continues to argue that there is insufficient comparative data for drugs that are granted conditional marketing authorization, health technology assessment bodies and payers in the EU generally agree that they need to find innovative solutions to work around these evidence gaps.

First Approvals Under EMA’s Adaptive Pathways May Be Just A Few Years Away

The first marketing authorizations under the European Medicines Agency’s hotly debated adaptive pathways concept for getting drugs to patients faster could be granted in just a few years’ time.

Related Content

Topics

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel